Tiziana Life Sciences is trading at $1.22, up 7.96%, with no confirmed company-specific catalyst for the move. - Its latest listed announcement was a September 30 filing for orphan-drug designation; its investor-relations release list shows no October 9 announcement. - Biotech-sector strength may be supportive: the provided sector context reports XBI up 2.50%, but this does not establish the reason for the stock’s larger gain. - No current volume information was available.